Johnson & Johnson MedTech announced FDA approval for the investigational device exemption (IDE) of its OTTAVA robotic surgical system, enabling clinical trials to commence in the U.S. The system aims to redefine robotic surgery with its innovative architecture and surgeon-centered features, addressing current unmet needs in the field. Designed to support robotic, laparoscopic, hybrid, and open surgery, the OTTAVA system incorporates low-profile robotic arms integrated into the operating table, optimizing space for surgical teams. It introduces advanced functionalities such as “twin motion,” enabling synchronized movements of the table and robotic arms for seamless intraoperative repositioning and multi-quadrant access.
Johnson & Johnson MedTech, a leader in global surgical technologies, is leveraging its Ethicon expertise and Polyphonic digital ecosystem to enhance the OTTAVA system with data-driven insights and collaboration tools. The system will feature Ethicon’s trusted surgical instrumentation, offering precision and consistency across surgical modalities. While still under development and not yet available for marketing, OTTAVA represents Johnson & Johnson MedTech's century-long commitment to advancing healthcare through innovation.
